The Importance of Different Modularity of the Polyethylene Insert for Tibial Component Migration and Adaptive Bone Remodeling After Uncemented Total Knee Arthroplasty Using Trabecular Metal Technology (TMT) Zimmer NexGen®, (Monoblock vs. Modular Design)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
In a prospective randomised study two uncemented tibial components with different polyethylene modularities (Trabecular Metal Technology (TMT) Zimmer NexGen® monobloc and TMT Zimmer NexGen® modular) used for total knee arthroplasty (TKA) is evaluated. Both tibial component coatings are designed to provide excellent condition for bone ingrowth.
The differences between the two tibial components are evaluated by measurements of migration of the tibial component assessed by Radiostereometric analysis (RSA) and measurements of the adaptive bone remodeling of the proximal tibial assessed by dual energy X-ray absorptiometry (DEXA).
| Condition | Intervention |
|---|---|
|
Arthrosis of the Knee |
Device: Zimmer NexGen® Trabecular Metal Technology (TMT), Monoblock Device: Zimmer NexGen® Trabecular Metal Technology (TMT), Modular |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | The Importance of Different Modularity of the Polyethylene Insert for Tibial Component Migration and Adaptive Bone Remodeling After Uncemented Total Knee Arthroplasty Using Trabecular Metal Technology (TMT) Zimmer NexGen®, (Monoblock vs. Modular Design) |
- migration of tibial component [ Time Frame: three years ] [ Designated as safety issue: Yes ]The differences between two tibial components are evaluated by measurements of migration of the tibial component assesed by Radiostereometric analysis (RSA) and measurements of the adaptive bone remodeling of the proximal tibial assesed by dual energy X-ray absorpitiometry (DEXA).
- Knee function [ Time Frame: three years ] [ Designated as safety issue: No ]knee function postoperativly assessed by Oxford Knee Score
| Estimated Enrollment: | 60 |
| Study Start Date: | July 2012 |
| Estimated Study Completion Date: | August 2025 |
| Estimated Primary Completion Date: | August 2015 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Zimmer NexGen®, Trabecular Metal Technology (TMT) Monoblock
The tibial component has a monoblock design
|
Device: Zimmer NexGen® Trabecular Metal Technology (TMT), Monoblock
A prospective randomized study where the patients are randomized too receive a monoblock tibial component with trabecular metal coating (TMT Zimmer NexGen®) or a modular tibial component (TMT Zimmer NexGen®). Both prostheses are available and approved by the FDA and CE. The only difference between the implants is that of the polyethylene insert (monoblock vs. modular). The operations are performed at the Department of Planned Elective Surgery Z, Gentofte Hospital by two experienced TKA surgeons that will be included in the research group. During surgery a minimum of 4 Tantalum markers (0.8 mm) is inserted in the bone of the proximal tibia and 6 markers are inserted in the polyethylene insert. |
|
Zimmer NexGen® Trabecular Metal Technology (TMT), Modular
The tibial component has a modular design
|
Device: Zimmer NexGen® Trabecular Metal Technology (TMT), Modular
A prospective randomized study where the patients are randomized too receive a monoblock tibial component with trabecular metal coating (TMT Zimmer NexGen®) or a modular tibial component (TMT Zimmer NexGen®). Both prostheses are available and approved by the FDA and CE. The only difference between the implants is that of the polyethylene insert (monoblock vs. modular). The operations are performed at the Department of Planned Elective Surgery Z, Gentofte Hospital by two experienced TKA surgeons that will be included in the research group. During surgery a minimum of 4 Tantalum markers (0.8 mm) is inserted in the bone of the proximal tibia and 6 markers are inserted in the polyethylene insert. |
Show Detailed Description
Eligibility| Ages Eligible for Study: | 40 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
The participants of the study are patients that have been scheduled for a primary TKA using the usual indications for TKA at the Department of Planned Elective Surgery Z, Gentofte Hospital.
Inclusion Criteria:
- Severe osteoarthrosis of the knee with indication for a TKA.
- Age between 40 and 70 years.
Exclusion Criteria:
- Diseases affecting the bone metabolism (osteoporosis, Pagets disease, hyperparathyreoidism etc.).
- Patients estimated not to be able to understand the "Information to patients" papers or do not want to participate in the study.
Contacts and Locations| Contact: Mikkel MA Andersen, Ph.D | 60 14 47 18 ext 0045 | mand0474@geh.regionh.dk |
| Contact: Michael MP Petersen, Professor | 35 45 35 45 ext 0045 | michael.moerk.petersen@rh.regionh.dk |
| Denmark | |
| Gentofte Hospital | Recruiting |
| Copenhagen, Denmak, Denmark, 2900 | |
| Contact: Mikkel MA Andersen, Ph.D. +45 60 14 47 18 ext +45 mand0474@geh.regionh.dk | |
| Principal Investigator: Mikkel MA Andersen, Ph.D | |
| Gentofte Hospital | Recruiting |
| Copenhagen, Denmark, 2900 | |
| Contact: Mikkel Rathsach Andersen, Ph.D +45 60 14 47 18 mand0474@geh.regionh.dk | |
| Principal Investigator: | Mikkel Rathsach Andersen, Ph.D | Rigshospitalet, Denmark |
More Information
Publications:
| Responsible Party: | Mikkel Rathsach Andersen, Læge, Ph.D, Rigshospitalet, Denmark |
| ClinicalTrials.gov Identifier: | NCT01637051 History of Changes |
| Other Study ID Numbers: | H-1-2012-033 |
| Study First Received: | July 6, 2012 |
| Last Updated: | July 9, 2012 |
| Health Authority: | Denmark: Danish Dataprotection Agency Denmark: Ethics Committee Denmark: The Regional Committee on Biomedical Research Ethics |
Additional relevant MeSH terms:
|
Joint Diseases Osteoarthritis Musculoskeletal Diseases Arthritis Rheumatic Diseases |
ClinicalTrials.gov processed this record on May 19, 2013